Tema Etfs LLC Makes New $260,000 Investment in Syndax Pharmaceuticals, Inc. $SNDX

Key Points

• Tema Etfs LLC has acquired 21,169 shares of Syndax Pharmaceuticals, valued at approximately $260,000, marking a new investment in the company during the first quarter.
• Wall Street analysts have given a consensus rating of "Buy" for Syndax Pharmaceuticals, with BTIG Research raising its target price from $43.00 to $56.00.
• In recent insider transactions, CEO Michael A. Metzger sold 7,534 shares, while Director Dennis Podlesak sold 19,200 shares, indicating a decrease in their respective holdings.

Tema Etfs LLC acquired a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 21,169 shares of the company's stock, valued at approximately $260,000.

Other institutional investors have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Syndax Pharmaceuticals by 3.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,748 shares of the company's stock worth $706,000 after purchasing an additional 1,811 shares in the last quarter. MetLife Investment Management LLC grew its stake in Syndax Pharmaceuticals by 6.2% during the 4th quarter. MetLife Investment Management LLC now owns 50,515 shares of the company's stock worth $668,000 after purchasing an additional 2,961 shares in the last quarter. E Fund Management Co. Ltd. grew its stake in Syndax Pharmaceuticals by 27.2% during the 1st quarter. E Fund Management Co. Ltd. now owns 16,031 shares of the company's stock worth $197,000 after purchasing an additional 3,428 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Syndax Pharmaceuticals by 2.5% during the 1st quarter. Bank of New York Mellon Corp now owns 229,758 shares of the company's stock worth $2,823,000 after purchasing an additional 5,497 shares in the last quarter. Finally, ProShare Advisors LLC grew its stake in Syndax Pharmaceuticals by 32.2% during the 4th quarter. ProShare Advisors LLC now owns 27,183 shares of the company's stock worth $359,000 after purchasing an additional 6,627 shares in the last quarter.

Syndax Pharmaceuticals Stock Performance

Shares of Syndax Pharmaceuticals stock traded down $0.18 on Tuesday, hitting $16.15. The stock had a trading volume of 1,301,483 shares, compared to its average volume of 2,247,317. Syndax Pharmaceuticals, Inc. has a 52-week low of $8.58 and a 52-week high of $22.50. The company has a current ratio of 4.71, a quick ratio of 4.55 and a debt-to-equity ratio of 2.06. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -4.15 and a beta of 0.72. The company's 50 day moving average price is $11.63 and its 200 day moving average price is $11.95.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.01) by $0.18. The business had revenue of $37.96 million during the quarter, compared to the consensus estimate of $26.64 million. Syndax Pharmaceuticals had a negative return on equity of 130.47% and a negative net margin of 428.48%.The business's quarterly revenue was up 984.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.80) EPS. On average, research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Wall Street Zen raised Syndax Pharmaceuticals to a "sell" rating in a research note on Tuesday, May 6th. Guggenheim reaffirmed a "buy" rating and set a $32.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. B. Riley raised Syndax Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, August 6th. Scotiabank lifted their price target on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a report on Tuesday, May 6th. Finally, UBS Group decreased their price target on Syndax Pharmaceuticals from $37.00 to $35.00 and set a "buy" rating for the company in a report on Tuesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of "Buy" and an average price target of $38.00.

Insider Activity at Syndax Pharmaceuticals

In other Syndax Pharmaceuticals news, Director Dennis Podlesak sold 19,200 shares of the company's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $15.84, for a total transaction of $304,128.00. Following the completion of the sale, the director directly owned 191,763 shares of the company's stock, valued at $3,037,525.92. This represents a 9.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael A. Metzger sold 7,534 shares of the company's stock in a transaction that occurred on Wednesday, July 16th. The shares were sold at an average price of $9.29, for a total value of $69,990.86. Following the sale, the chief executive officer directly owned 298,661 shares of the company's stock, valued at approximately $2,774,560.69. This represents a 2.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 47,230 shares of company stock valued at $684,527. 4.10% of the stock is owned by company insiders.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).